VEA
INDV icon

Virtus ETF Advisers’s Indivior Pharmaceuticals INDV Stock Holding History

Virtus ETF Advisers’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Buy
6,301
+301
+5% +$10.9K 0.1% 236
2026
Q1 		$183K Hold
6,000
– – 0.09% 253
2025
Q4 		$215K Buy
+6,000
New +$183K 0.1% 219

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus ETF Advisers's INDV Position: Q2 2026 in Review

Virtus ETF Advisers increased its Indivior Pharmaceuticals (INDV) stake by 5% in Q2 2026, buying an estimated $10.9K and bringing the position to 6,301 shares worth $259K. The position accounts for 0.1% of the portfolio, ranked #236.

Virtus ETF Advisers first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Virtus ETF Advisers held 6,301 shares of Indivior Pharmaceuticals worth $259K as of Q2 2026.
  • Virtus ETF Advisers bought 301 Indivior Pharmaceuticals shares in Q2 2026, an estimated $10.9K.
  • Indivior Pharmaceuticals made up 0.1% of Virtus ETF Advisers's portfolio in Q2 2026, its #236 holding.
  • Virtus ETF Advisers first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.